[Secondary pigment dispersion syndrome following 24 years of medically induced mydriasis (author's transl)].
A 59-year-old male patient with congenital central cataract was treated for 24 years with atropine, scopolamine, and thyramine hydrochloride eye drops to achieve a permanent mydriasis for optical reasons. He developed a peculiar secondary pigment dispersion syndrome, which is interpreted as a complication of the excessive pupillary excursion on the anterior lens surface following iatrogenic mydriasis. This may be differentiated from the idiopathic and other more common types of secondary pigment dispersion syndrome, mainly by the location of the defects in the pigment epithelium of the iris.
D001285:Atropine / Q000009:adverse effects; D002386:Cataract / Q000188:drug therapy; D006801:Humans; D008297:Male; D009184:Mydriatics / Q000009:adverse effects*; D010859:Pigmentation Disorders / Q000139:chemically induced* / Q000473:pathology; D012601:Scopolamine / Q000009:adverse effects
D009184:Mydriatics; D001285:Atropine; D012601:Scopolamine
Sekundäres Pigmentd-dispersions-Syndrom nach medikamentöser Dauer-Mydriasis über 24 Jahre.